Less DAPT Can Help Avoid Bleeding in High-Risk Patients Post-PCI – CRT Session
The TWILIGHT studies’ findings support the use of ticagrelor in selected high-risk patients as a bleeding-avoidance strategy after percutaneous coronary intervention. That was only one of the many takeaway messages from Saturday’s landmark session on antiplatelet therapy at CRT 2021 Virtual.